Breaking News

JPMorgan Said to Mull Raising Some Staff Salaries at Least 20%
Tweet TWEET

Manufacture of BNC101 Commences at Lonza

Manufacture of BNC101 Commences at Lonza

ADELAIDE, South Australia, April 23, 2013 (GLOBE NEWSWIRE) -- Bionomics
Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated
manufacturing activities for BNC101, its lead anti-cancer stem cell candidate
following completion of key preclinical studies.

Dr Deborah Rathjen, Bionomics CEO & Managing Director commented, "The start of
manufacturing activities for BNC101 signals a significant step towards
clinical trials. We anticipate that Bionomics will commence clinical trials of
BNC101 in 2014".

"BNC101 is a novel therapeutic antibody designed to target cancer stem
cells.Eliminating cancer stem cells represents a new cancer treatment
paradigm that could offer a distinct advantage over existing treatment
strategies and a solution for resistance to chemotherapy," said Dr Rathjen.

Lonza will manufacture BNC101 at its facility in Slough, UK.

"We consider Lonza to be a leader in the area of contract development and
manufacturing, and we are pleased to announce this important milestone in the
BNC101 development program," said Christopher Reyes, Ph.D., Vice President of
Research and Development Biologics.

Preclinical data has shown that BNC101 has demonstrated functional activity
against LGR5, a high value cancer stem cell receptor. In addition, BNC101
significantly reduces cancer stem cell frequency and prevents tumour
re-growth in long term animal studies involving primary colorectal cancer
patient samples with multiple underlying gene mutations.

The clinical strategy for BNC101 will target solid tumours expressing LGR5
where there is a high rate of relapse. Colorectal cancer and pancreatic cancer
have been chosen as initial priority indications.

About Bionomics Limited

Bionomics (ASX:BNO) is an Australian based international biotechnology company
which discovers and develops innovative therapeutics for cancer and diseases
of the central nervous system. Bionomics has small molecule and antibody
product development programs in the areas of cancer, anxiety, and memory loss.
Its oncology approach includes cancer stem cell therapeutics as well as
vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid
tumour types,is based upon the identification of a novel compound that
potently and selectively restricts blood flow within tumours. BNC105 offers
blockbuster potential if successfully developed. A clinical program is also
underway for the treatment of anxiety disorders and depression based on
IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143
is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four
proprietary technology platforms: Angene®, a drug discovery platform which
incorporates a variety of genomics tools to identify and validate novel
angiogenesis targets (involved in the formation of new blood vessels);
MultiCore®, a diversity orientated chemistry platform for the discovery of
small molecule drugs; ionX® , a set of novel technologies for the
identification of drugs targeting ion channels for diseases of the central
nervous system; and CSC Rx Discovery™, which identifies antibody and small
molecule therapeutics that inhibit the growth of cancer stem cells. These
platforms drive Bionomics' pipeline and underpin its established business
strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of
the United States' Private Securities Litigation Reform Act of 1995. Any
statements contained in this presentation that relate to prospective events or
developments, including, without limitation, statements made regarding
Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375,
our acquisition of Eclipse Therapeutics and ability to develop products from
their platform, its licensing deal with Ironwood Pharmaceuticals, drug
discovery programs and pending patent applications are deemed to be
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "projects," "forecasts," "will" and similar expressions are
intended to identify forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by these forward-looking statements, including
risks related to our available funds or existing funding arrangements, a
downturn in our customers' markets, our failure to introduce new products or
technologies in a timely manner, Ironwood's decisions to continue or not
continue development of IW-2143, regulatory changes, risks related to our
international operations, our inability to integrate acquired businesses and
technologies into our existing business and to our competitive advantages, as
well as other factors. Results of studies performed on competitors products
may vary from those reported when tested in different settings. Subject to the
requirements of any applicable legislation or the listing rules of any stock
exchange on which our securities are quoted, we disclaim any intention or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this announcement.

CONTACT: FOR FURTHER INFORMATION PLEASE CONTACT:

         Bionomics Limited

         Dr Deborah Rathjen
         CEO & Managing Director
         +618 8354 6101 /
         0418 160 425
         drathjen@bionomics.com.au
        
         Monsoon Communications

         Rudi Michelson
         +613 9620 3333
         rudim@monsoon.com.au
        
         The Trout Group

         Lauren Glaser
         +1 646 378 2972
         lglaser@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.